secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2025-01-28T23:59:59+00:00
Accession:  0001493152-25-003985
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma expands Phase 2 glioblastoma trial; adds sites, extends timeline through Jan 2026
--------------------------------------------------------------------------------

- Change Order with Theradex increases Phase 2 patients from 15 to 16 and sites from 4 to 6.
- Total budget limited to $5,308,294; covers activities through 31 January 2026.
- Protocol amendments versions 2.0 and 3.0 added; safety teleconferences expanded for medical monitor review.
- Two sites (UNC and Georgetown) activated earlier than anticipated, driving budget increase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225003985/0001493152-25-003985-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225003985/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-003985

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer